Pablo Valenzuela, Vice President R & D at Chiron Corp., faces several ways in which scarce resources on several promising projects awarded. These decisions will also determine the position of Chiron in several emerging biotechnology and diagnostic markets, including tests for hepatitis C, HIV, and others. Valenzuela to examine the ability of Chiron, its strategy and the nature of the opportunity, including the impact of these decisions on joint-venture partner.

Pablo Valenzuela, Vice President R & D at Chiron Corp., faces several ways in which scarce resources on several promising projects awarded. These decisions will also determine the position of Chiron in several emerging biotechnology and diagnostic markets, including tests for hepatitis C, HIV, and others. Valenzuela to examine the ability of Chiron, its strategy and the nature of the opportunity, including the impact of these decisions on joint-venture partner.
«Hide

from
Steven C. Wheelwright,
Brian Elliott
Source: Harvard Business School
20 pages.
Publication Date: Apr 16, 1993. Prod #: 693052-PDF-ENG
Chiron Corp. HBR case solution